BTIG Research Reaffirms Buy Rating for Mobia Medical (NASDAQ:MOBI)

Mobia Medical (NASDAQ:MOBI)‘s stock had its “buy” rating reiterated by equities researchers at BTIG Research in a research report issued on Wednesday,Benzinga reports. They currently have a $19.00 price target on the stock. BTIG Research’s price objective would suggest a potential upside of 51.03% from the stock’s current price.

A number of other research firms have also recently weighed in on MOBI. Wall Street Zen raised Mobia Medical from a “sell” rating to a “hold” rating in a report on Sunday, June 14th. Wolfe Research started coverage on Mobia Medical in a research note on Tuesday, June 2nd. They issued an “outperform” rating for the company. Bank of America initiated coverage on Mobia Medical in a report on Tuesday, June 2nd. They set a “buy” rating and a $16.00 price target on the stock. JPMorgan Chase & Co. assumed coverage on shares of Mobia Medical in a research note on Tuesday, June 2nd. They set an “overweight” rating and a $15.00 price objective on the stock. Finally, The Goldman Sachs Group started coverage on shares of Mobia Medical in a report on Tuesday, June 2nd. They issued a “buy” rating and a $31.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.25.

Mobia Medical Price Performance

MOBI stock opened at $12.58 on Wednesday. Mobia Medical has a 1 year low of $10.19 and a 1 year high of $15.29. The company has a market capitalization of $418.27 million and a PE ratio of -0.65. The company has a fifty day moving average of $12.54.

Mobia Medical (NASDAQ:MOBI) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.27). The firm had revenue of $13.51 million for the quarter. The company’s quarterly revenue was up 102.4% on a year-over-year basis. Analysts predict that Mobia Medical will post -2.5 EPS for the current fiscal year.

Insider Activity at Mobia Medical

In other news, CFO Nelson Bunker Curnes bought 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 9th. The shares were purchased at an average price of $12.79 per share, with a total value of $63,950.00. Following the completion of the acquisition, the chief financial officer directly owned 366,997 shares in the company, valued at approximately $4,693,891.63. This trade represents a 1.38% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Mobia Medical News Roundup

Here are the key news stories impacting Mobia Medical this week:

• Positive Sentiment: Second-quarter revenue reached $13.5 million, up 102% year over year, while gross margin was a strong 83.2%. Management also reported durable two-year clinical benefits from its VNS-REHAB stroke-recovery therapy, including improvements in motor function, daily living activities and quality of life. Mobia Medical Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Mobia Medical raised approximately $134 million in net proceeds through its initial public offering, providing additional capital to support commercialization, research and corporate operations. Mobia Medical Q2 2026 Earnings Call Highlights
• Positive Sentiment: The company forecast 2026 revenue of $54 million to $56 million, representing approximately 69% to 75% growth and exceeding the roughly $53.5 million analyst consensus. Mobia Medical Forecasts 2026 Revenue
• Neutral Sentiment: Reported short-interest data showed zero shares sold short and a zero-day short-interest ratio, but the accompanying percentage change was listed as “NaN,” making the data unreliable and unlikely to provide a meaningful trading signal.
• Negative Sentiment: Mobia Medical reported a $1.10 per-share loss, wider than the expected $0.83 loss. The company remains unprofitable, and analysts expect a full-year loss of approximately $2.50 per share, which may keep pressure on the stock despite rapid top-line growth. Mobia Medical Quarterly Earnings Report

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.